Biosight Ltd. Revenue and Competitors

Lod,

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Biosight Ltd.'s estimated annual revenue is currently $620k per year.(i)
  • Biosight Ltd.'s estimated revenue per employee is $155,000

Employee Data

  • Biosight Ltd. has 4 Employees.(i)
  • Biosight Ltd. grew their employee count by -33% last year.

Biosight Ltd.'s People

NameTitleEmail/Phone
1
VP Medical AffairsReveal Email/Phone
2
Clinical Trials DirectorReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$99.4M45840%N/AN/A
#2
$20.6M13322%N/AN/A
#3
$156.1M146-70%$145MN/A
#4
$3.5M45-25%$150MN/A
#5
$1.6M210%$459.5MN/A
#6
$67.3M31016%$180.7MN/A
#7
$8.5M55-2%N/AN/A
#8
$256.3M10259%$168.5MN/A
#9
$2.8M18-33%N/AN/A
#10
$9.1M59-9%N/AN/A
Add Company

What Is Biosight Ltd.?

Biosight is a private Phase 2 clinical stage biotech company developing innovative therapeutics for hematological malignancies and disorders. Biosight's lead product, BST-236 (aspacytarabine), is an innovative proprietary anti-metabolite which addresses unmet medical needs by enabling high-dose chemotherapy with reduced systemic toxicity. BST-236 is currently being investigated as a single agent in a Phase 2b for first-line treatment of acute myeloid leukemia (AML), following completion of a Phase 1/2a study which demonstrated tolerability with promising efficacy in the challenging population of AML patients unfit for standard of care chemotherapy. A Phase 2 study in relapsed/refractory AML and myelodysplastic syndrome (MDS) will be launched in 2020 under a collaboration agreement recently signed with the European cooperative group, GFM.

keywords:N/A

N/A

Total Funding

4

Number of Employees

$620k

Revenue (est)

-33%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2.4M1417%N/A
#2
$3.5M30114%N/A
#3
$12.7M6442%N/A
#4
$10.2M7111%N/A
#5
$22M7414%N/A